Get In Touch

Chikungunya is a vector-transmitted viral disease caused by chikungunya virus i.e. CHIKV. CHIKV is an RNA virus belonging to Alphavirus genus of family Togaviridae. The disease was first detected in 1952 in southern Tanzania during an outbreak. The term chikungunya, which is borrowed from Kimakonde language, literally means ‘to become contorted’. The term was coined due to the stooped or curved appearance of sufferers having arthralgia (joint pain). Chikungunya is transmitted by day-biting infected mosquitoes, which are primarily of two types: Aedes aegypti and Aedes albopictus. The virus may also be circulated within different animals including rodents and birds. The disease is characterized by fever and joint pain. Other symptoms such as joint swelling, muscle pain, headache, fatigue, nausea, and rash are also observed. Most people suffering from chikungunya recover within a week; however, joint pain is often unbearable and it varies in duration. The disease can be diagnosed by testing the blood for antibodies against the virus (i.e. serological testing) or by detecting viral RNA in blood (i.e. molecular testing). Often the chikungunya infection is misdiagnosed with dengue or Zika virus in the areas where the latter two are prevalent, as all the three infections manifest similar symptoms.

According to the World Health Organization (WHO), chikungunya occurs in Asia including the Indian subcontinent and Africa with relatively low levels of human infection. However, in the year 1999–2000, a large outbreak occurred in the Democratic Republic of Congo and in 2006–2007, in India and Gabon. Thereafter, several cases were reported in other Southeast Asian countries and also in European countries. Since 2013, cases have been reported in France, North American countries, and Latin American countries also. So far, chikungunya is a disease with no cure or vaccines. Treatment is generally symptom-oriented and it aims at relieving the symptoms. The disease prevention is focused on the prevention of mosquito bites and prevention and control of mosquito infestation.

The global chikungunya diagnosis market is witnessing rapid growth, owing to the increasing incidence of chikungunya worldwide, rising awareness about mosquito-transmitted infections, and government initiatives regarding the prevention and control of mosquito infestation and the disease. Other factors driving the market for chikungunya diagnosis are constant government efforts regarding the prevention of mosquito breeding and general awareness among people about mosquito bites and the resulting infections. Additionally, the rising unmet needs for chikungunya diagnosis in Asia and Africa are likely to provide growth opportunities for the global chikungunya market during the forecast period. However, lack of appropriate treatment and vaccines and misdiagnosis of chikungunya with dengue and Zika virus infections may hamper the growth of the global market during the same period.  Also, factors such as lack of awareness in certain underdeveloped countries, shortage of proper diagnostic services along with skilled professionals, and scarcity of funds in these countries may lead to sluggish growth of the global market in the near future.

The chikungunya diagnosis market can be segmented on the basis of technique, end-user, and region. Chikungunya can be diagnosed by serological testing techniques or molecular testing techniques. Serological testing involves enzyme-linked immunosorbent assays (ELISA) carried out for detecting the presence of IgG and IgM anti-chikungunya antibodies. Molecular testing involves reverse transcriptase–polymerase chain reaction (RT–PCR) carried out for detecting the presence of viral RNA. The market can be segmented on the basis of end-user into diagnostic laboratories, hospitals, and others (academic & research institutes, biotechnology & pharmaceutical companies). The diagnostic laboratories segment is expected to account for a major share of the market during the forecast period, due to increasing incidence of mosquito-transmitted diseases and high investments in diagnostic laboratories.

Geographically, the chikungunya diagnosis market has been segmented into five regions viz. Europe, North America, Latin America, Asia Pacific, and Middle East & Africa. North America holds a major share of the global market, due to extensive R&D activities in the health care sector in the region including ongoing corporate and government efforts for the development of new products. The market in Asia Pacific is projected to expand at a rapid pace, due to high prevalence of mosquito-transmitted diseases. Additionally, alliances among the western market players is another factor stimulating the growth of the chikungunya diagnosis market in the region.

Key players operating in the global chikungunya diagnosis market are Abbott Laboratories, Alere Inc., Becton, Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories, Danaher Corporation, Hologic, Inc., MedMira Inc., Merck KGaA, QIAGEN, Roche Molecular Systems Inc., Siemens Healthcare, and Thermo Fisher Scientific, Inc.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Chikungunya Diagnosis Market

Pre Book